Drugmakers hurrying experimental Alzheimer’s drugs into late-stage testing may be undermining their ultimate chance at success.
The halting progress in the race to develop new Alzheimer’s drugs was on display at the International Conference on Alzheimer’s Disease in Chicago this week. Great expectations and a desire for quick results were tempered by the setbacks of some [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment